Skip to main content
. 2021 Jan 9;11(1):98. doi: 10.3390/diagnostics11010098

Figure 3.

Figure 3

Diagnostic performance of serum biomarkers for predicting advanced fibrosis in NAFLD patients. ROC curves of serum biomarkers for the diagnosis of advanced fibrosis in NAFLD patients. AUROC (95% CI): 0.66 (0.50–0.82) for AAR, 0.87 (0.79–0.95) for APRI, 0.91 (0.84–0.97) for FIB-4, 0.92 (0.85–0.99) for Forns index, 0.89 (0.81–0.97) for NFS, 0.94 (0.90–0.99) for HFS, 0.79 (0.66–0.93) for BARD. Advanced fibrosis was defined as histologic liver fibrosis ≥F3 according to Brunt/Kleiner et al. for NAFLD [27,28]. AAR, AST to ALT ratio; APRI, AST to Platelet Ratio Index; BARD, BMI AST/ALT Ratio Diabetes; Fib-4, fibrosis 4; HFS, Hepamet fibrosis score; NFS, NAFLD fibrosis score.